{"entity":{"id":"nct07543848","kind":"trial","name":"A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemot","aka":[],"tldr":"A phase 2 trial of serplulimab in colorectal cancer, run by Chongqing University Cancer Hospital, not yet recruiting.","summary":"A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer is a phase 2, interventional study registered as NCT07543848 by Chongqing University Cancer Hospital, with a registry enrolment figure of 20 participants, started 2026-05-01 and due to reach its primary completion in 2028-12-31. Interventions recorded: Serplulimab; Oncolytic Virus H101; XELOX Chemotherapy; Short-course Radiotherapy. Conditions listed: Rectal Neoplasms; Rectal Adenocarcinoma. Primary outcome: 1-year Clinical Complete Response Rate. Colorectal eligibility wording from the registry: \"Histologically confirmed low rectal adenocarcinoma, with tumor located ≤5 cm from the anal verge\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07543848","url":"https://clinicaltrials.gov/study/NCT07543848"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","imrt-igrt"],"targets":[],"drugs":["serplulimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07543848","phase":"2","setting":"A Prospective, Multicenter, Single-Arm Phase II Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (cT1-3N0M0)","sponsor":"Chongqing University Cancer Hospital","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07543848/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"serplulimab","kind":"drug","name":"Serplulimab","route":"/drugs/serplulimab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}